Jounce Therapeutics EBIT

Jounce Therapeutics (JNCE) currently reports a EBIT of $-52M as of December 2022. That compares with $-61M in the prior-year period — up 13.8% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Jounce Therapeutics's EBIT history and peer comparisons.

Jounce Therapeutics's EBIT increased from $-61M to $-52M — a 13.8% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jounce Therapeutics's EBIT of $-52M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Jounce Therapeutics reported $-52M in EBIT as of December 2022. That compares with $-61M in the prior-year period — up 13.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-52M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Jounce Therapeutics, and consider following JNCE for alerts when major investors trade the stock.